Correction to the release of BBS-Bioactive Bone Substitutes Plc revealed on 21.12.2020 at 16:30 CET Helsinki Stock Trade:BONEH

Correction to the release of BBS-Bioactive Bone Substitutes Plc revealed on 21.12.2020 at 16:30 CET Helsinki Stock Trade:BONEH

The launch of BBS-Bioactive Bone Substitutes’ economical calendar and Once-a-year Normal Conference in 2021 posted by BBS-Bioactive Bone Substitutes Plc on 21.12.2020 at 16:30 CET has been corrected. A clause in accordance with the Market place Abuse Regulation has been eradicated from the launch. The corrected launch is in entirety beneath.

BBS-Bioactive Bone Substitutes’ monetary calendar and Annual Standard Assembly in 2021

Through the calendar year 2021, BBS-Bioactive Bone Substitutes Plc (”BBS”) will publish the economical data as follows: 

Financial Statements Release for the yr 2020               Wed, 24 February 2021  

50 percent-year financial report January-June 2021                   Wed, 25 August 2021        

The Once-a-year Report for the 12 months 2020 will be posted on the week 13/2021. 

The Yearly Typical Conference is planned to be held on Wednesday, 28 April 2021. The Board of Directors of BBS Plc will convene the assembly at a later day.  

Much more information:
Ilkka Kangasniemi, CEO
tel. +358 40 7080 307
e-mail: [email protected]

Distribution:
Nasdaq Helsinki Oy
Nasdaq Stockholm AB
Primary Media
www.bbs-artebone.fi

BBS – Bioactive Bone Substitutes Ltd

BBS-Bioactive Bone Substitutes Plc is a Finnish orthobiologic biotech firm. We have developed a new products for healing of hard bone fractures and for resolving the challenges in bone healing. Our mission is to supply new technology medicinal solutions for the orthopedic surgical procedure. The analysis and improvement in the discipline of medication needs perseverance and bravery to produce new points.  We have more than 20 many years of know-how in this. Our functions are characterised by major abilities, innovativeness and committed and fully commited staff members. The 1st products, ARTEBONE® paste, is ready and the application method for the CE-marking enabling commercialization is in progress.

Extra information and facts: www.bbs-artebone.fi.

BBS-Bioactive Bone Substitutes Plc shares are detailed on the Nasdaq 1st North Progress Market Finland and Nasdaq 1st North Progress Market place Sweden. The company’s Accredited Adviser is Stockholm Qualified Advisers AB, p. +46 70 5516 729, [email protected]